Northwire Canada EditionTuesday, August 25, 2026
Northwire
GOLD 4694.50 −0.1% SILVER 68.68 +0.1% COPPER 6.71 +1.6% OIL 82.36 −3.1% PALLADIUM 1333.20 −2.2% MNRG 0.095 +0.0% AG 29.35 +1.6% CTV 0.140 +16.7% OTMC 0.600 +34.8% OPW 0.130 +4.0% HI 0.165 +10.0% VCU 1.33 +1.5% DLTA 0.175 −5.4% EMO 0.400 −1.2% GR 0.070 +0.0% MGG 0.400 +2.6% EVI 0.520 −5.5% AVL 9.43 +17.7% VCG 1.50 +9.5% TTS 2.26 −13.1% SCMI 1.90 +2.7% GOLD 4694.50 −0.1% SILVER 68.68 +0.1% COPPER 6.71 +1.6% OIL 82.36 −3.1% PALLADIUM 1333.20 −2.2% MNRG 0.095 +0.0% AG 29.35 +1.6% CTV 0.140 +16.7% OTMC 0.600 +34.8% OPW 0.130 +4.0% HI 0.165 +10.0% VCU 1.33 +1.5% DLTA 0.175 −5.4% EMO 0.400 −1.2% GR 0.070 +0.0% MGG 0.400 +2.6% EVI 0.520 −5.5% AVL 9.43 +17.7% VCG 1.50 +9.5% TTS 2.26 −13.1% SCMI 1.90 +2.7%
Production / Operations Routine +

Ynvisible Secures SEK 3.0 Million in Grants to Advance Sustainable Manufacturing and Medical E-Paper Applications

Ynvisible Secures Incremental Grant Funding Amidst Continued Dilution and Commercial Scaling Phase

Executive Summary
  • Ynvisible Interactive Inc. secured SEK 3.0 million (approx. CAD$400,000) in grants from Swedish innovation organizations on May 28, 2026.
  • Funding is allocated to two specific projects: R2R-MICROBAT for battery manufacturing and MedPrint for medical-grade e-paper display production.
  • The MedPrint initiative targets a potential capacity of up to 10 million units annually in Norrköping.
  • Management views the funding as validation of their sustainable manufacturing capabilities and expansion into healthcare diagnostics.
  • This follows a series of private placements closed between March and May 2026, totaling over $1.3 million in gross proceeds from equity financing.
Material Impact
  • The grant represents non-dilutive capital which is positive for cash flow but immaterial relative to the company's overall burn rate and recent equity dilution.
  • Previous private placements (March-May 2026) raised approximately $1.3 million in equity, indicating a reliance on shareholder capital rather than commercial revenue to fund operations.
  • The grant amount ($400k) is roughly equivalent to one month of the previous financing rounds and does not materially alter the company's runway or valuation thesis compared to the dilution risk from recent financings.
  • News aligns with historical projections regarding MedPrint scaling; no new commercial contracts were announced alongside this funding, limiting immediate revenue impact.
  • Market reaction has been muted historically on similar announcements (price remained flat around $0.10-$0.12 during financing closings in April/May 2026).
YNV · Price
Company Overview
  • Core Business: Ynvisible develops ultra-low power printed e-paper displays for healthcare, industrial, and automotive applications.
  • Flagship Projects: MedPrint (medical diagnostics) and R2R-MICROBAT (sustainable battery manufacturing).
  • Manufacturing: Operates a roll-to-roll facility in Norrköping, Sweden; utilizes CCL Design for high-volume production transfer to China.
  • Commercial Status: Transitioned from development to commercial execution in 2025 with ~12 confirmed orders generating CAD$800k revenue; pipeline quoted value estimated at CAD$30 million but conversion rate remains unverified.
Read the original news release →

More from Ynvisible Interactive Inc.